Publications by authors named "Shubin Tang"

Claim this Profile
E
Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trial.
Yuankai Shi, Minghong Bi, Qingshan Li, Guolei Wang, Jianhua Chen, Shubin Tang

Cancer Pathog Ther· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001).
Hua-Jun Chen, Hai-Yan Tu, Yanping Hu, Yun Fan, Guowu Wu, Shubin Tang

J Hematol Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation.
Tian Tian, Min Yu, Juan Li, Maoqiong Jiang, Daiyuan Ma, Shubin Tang

Front Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Calpain Small Subunit 1 Protein in the Prognosis of Cancer Survivors and Its Clinicopathological Correlation.
Shubin Tang, Qiushi Yin, Fangteng Liu, Yi Zhang

Biomed Res Int· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of lncRNA FEZF1 antisense RNA 1 over-expression in oncologic outcomes of patients with solid tumors.
Yi Zhang, Qiu-Xi Yang, Ting-Ting Peng, Li-Juan Wang, Guo-Liang Xiao, Shu-Bin Tang

Medicine (Baltimore)· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis